D.E. Shaw & Co
ABEO icon

D.E. Shaw & Co’s Abeona Therapeutics ABEO Stock Holding History

D.E. Shaw & Co’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$453K Sell
101,065
-4,900
-5% -$24.5K ﹤0.01% 3898
2025
Q4 		$558K Sell
105,965
-20,419
-16% -$103K ﹤0.01% 3872
2025
Q3 		$667K Buy
+126,384
New +$802K ﹤0.01% 3707
2022
Q3 		– Sell
-49,220
Closed -$256K – 5138
2022
Q2 		$256K Sell
49,220
-32,146
-40% -$163K ﹤0.01% 4429
2022
Q1 		$641K Sell
81,366
-19,380
-19% -$133K ﹤0.01% 4221
2021
Q4 		$849K Buy
+100,746
New +$1.85M ﹤0.01% 4063
2021
Q1 		– Sell
-3,331
Closed -$131K – 3985
2020
Q4 		$131K Sell
3,331
-5,043
-60% -$172K ﹤0.01% 3786
2020
Q3 		$214K Buy
8,374
+949
+13% +$59.8K ﹤0.01% 3576
2020
Q2 		$541K Sell
7,425
-1,770
-19% -$122K ﹤0.01% 3315
2020
Q1 		$483K Sell
9,195
-1,123
-11% -$75K ﹤0.01% 3230
2019
Q4 		$843K Buy
10,318
+4,226
+69% +$298K ﹤0.01% 3093
2019
Q3 		$344K Buy
6,092
+5,595
+1,126% +$419K ﹤0.01% 3388
2019
Q2 		$59K Buy
+497
New +$83.3K ﹤0.01% 3578
2016
Q4 		– Sell
-497
Closed -$75K – 3406
2016
Q3 		$75K Buy
+497
New +$48.6K ﹤0.01% 3306
2016
Q1 		– Sell
-520
Closed -$44K – 3367
2015
Q4 		$44K Buy
+520
New +$52.2K ﹤0.01% 3719

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co's ABEO Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Abeona Therapeutics (ABEO) stake by 4.6% in Q1 2026, selling an estimated $24.5K and leaving 101,065 shares worth $453K. The position accounts for ﹤0.01% of the portfolio, ranked #3898.

D.E. Shaw & Co first reported a position in ABEO in Q4 2015 and has held it in 15 quarters since. The position peaked at $849K in Q4 2021. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • D.E. Shaw & Co held 101,065 shares of Abeona Therapeutics worth $453K as of Q1 2026.
  • D.E. Shaw & Co sold 4,900 Abeona Therapeutics shares in Q1 2026, an estimated $24.5K.
  • Abeona Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #3898 holding.
  • D.E. Shaw & Co first reported a position in Abeona Therapeutics in Q4 2015 and has held it in 15 quarters since.
  • D.E. Shaw & Co's Abeona Therapeutics position peaked at $849K in Q4 2021.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.